Connect Biopharma Presented Additional Data From Its Atopic Dermatitis Trial In China At The 2023 World Congress Of Dermatology
Portfolio Pulse from Benzinga Newsdesk
Connect Biopharma has presented additional data from its atopic dermatitis trial in China at the 2023 World Congress of Dermatology. The data, from four poster presentations, detailed the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported outcomes from the initial 16-week treatment period with rademikibart (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis in the pivotal CN002 trial.
July 10, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The presentation of positive data from Connect Biopharma's atopic dermatitis trial could potentially boost investor confidence in the company and its product, rademikibart.
The presentation of positive data from a clinical trial is typically seen as a positive event for a biopharmaceutical company. This could potentially lead to increased investor confidence in the company and its product, which could in turn lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100